What would you like to look for?
Site search
Search filters

Warteck Invest completes Capital Increase and listing of the new shares

8 July 2024

Warteck Invest is one of the oldest real estate companies listed on the SIX Swiss Exchange and is focusing on residential and business properties in Switzerland. In the rights offering to support the growth strategy of Warteck Invest 61'875 new registered shares were offered (gross proceeds of approximately CHF 94.7 million).

Narrowin and EnBW enter partnership

15 April 2024

The German energy supplier EnBW enters into a partnership with narrowin GmbH, a Swiss cybersecurity start-up. As part of the cooperation, EnBW is also making a financial investment in narrowin via EnPulse Ventures GmbH.

Sale of T3 Pharmaceuticals AG to Boehringer Ingelheim

23 November 2023

T3 Pharmaceuticals AG, a biotechnology company with its headquarter in Allschwil, Switzerland has been acquired by Boehringer Ingelheim, a leading family-owned, research-driven biopharmaceutical company based in Ingelheim, Germany...

LimmaTech Biologics Raises USD 37m Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

12 October 2023

LimmaTech Biologics AG announced the closing of a USD 37m (CHF 33m) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund.

Follow-On Offering of Oculis Holding AG

8 June 2023

Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, has placed a follow-on public offering of 3.5m ordinary shares at a public offering price of USD 11.50 per ordinary share, for gross proceeds of USD 40.25m, before deducting underwriting discounts and commissions and offering expenses.

Herbonis sold to Innov Ad

23 May 2023

Innov Ad N.V., a leading provider of animal nutrition and health solutions, acquired its Swiss competitor Herbonis AG and its subsidiaries in Switzerland, France and the UK. Herbonis specializes in producing natural solutions for...

Oculis to list on NASDAQ

7 March 2023

Oculis Holding AG ("Oculis") a global biopharmaceutical company purposefully driven to save sight and improve eye care, listed its shares on Nasdaq after successfully closing the business combination between European Biotech Acquisition Corp. (“EBAC”).

Oculis SA and European Biotech Acquisition Corp announce business combination

26 October 2022

Oculis, SA, a global biopharmaceutical company developing treatments to save sight and improve eye care with breakthrough innovations and European Biotech Acquisition Corp (NASDAQ: EBAC), a special purpose acquisition company (SPAC), announced they have entered into a definitive business combination agreement.

VISCHER advised Forty51 Ventures in the closing of its first fund

12 September 2022

VISCHER advised Forty51 Ventures, a Biotech venture capital firm, on its first fund, Forty51 Ventures Fund I SCSp, FIAR, which raised USD 43 million in a first closing and is domiciled in Luxemburg (the "Fund").

EBL sells telecom division to Sunrise

5 September 2022

EBL has been active in the telecom business since 2000 and owns telecom networks in around 200 communities in Switzerland. At the same time, EBL has been successfully pursuing a strong expansion of its business with renewable...